Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis

Barbara F. Eichhorst, Kirsten Fischer, Anna-Maria Fink, Thomas Elter, Clemens M. Wendtner, Valentin Goede, Manuela Bergmann, Stephan Stilgenbauer, Georg Hopfinger, Matthias Ritgen, Jasmin Bahlo, Raymonde Busch, Michael Hallek, for the German CLL Study Group (GCLLSG)

Blood (2011) 117 (6): 1817–1821.

https://doi.org/10.1182/blood-2010-04-282228

Published: 2011

Includes: Supplemental data

Journal Articles

Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL: A Multicenter Phase II Trial of the German CLL Study Group (GCLLSG).

Kirsten Fischer, MD, Paula Cramer, MD, Stephan Stilgenbauer, MD, Raymonde Busch, Leopold Balleisen, MD, Julia Kilp, MD, Anna-Maria Fink, MD, Sebastian Boettcher, MD, Matthias Ritgen, MD, Michael Kneba, MD, PhD, Peter Staib, MD, Hartmut Döhner, MD, Silke Schulte, Barbara F. Eichhorst, MD, Michael Hallek, MD, Clemens-Martin Wendtner, MD, the German CLL Study Group (GCLLSG)

Blood (2009) 114 (22): 205.

https://doi.org/10.1182/blood.V114.22.205.205

Published: 2009

Journal Articles

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

Blood (2009) 114 (16): 3382–3391.

https://doi.org/10.1182/blood-2009-02-206185

Published: 2009

Includes: Supplemental data

Journal Articles

Quantitative MRD Assessments Predict Progression Free Survival in CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab – a Prospective Analysis in 471 Patients from the Randomized GCLLSG CLL8 Trial

Sebastian Boettcher, MD, Kirsten Fischer, MD, Stephan Stilgenbauer, MD, PhD, Raymonde Busch, Günter Fingerle-Rowson, MD, PhD, Anna-Maria Fink, MD, Hartmut Döhner, MD, PhD, Michael Hallek, MD, PhD, Michael Kneba, MD, PhD, Matthias Ritgen, MD, on Behalf Of GCLLSG

Blood (2008) 112 (11): 326.

https://doi.org/10.1182/blood.V112.11.326.326

Published: 2008

Journal Articles

Standardized MRD Flow and ASO IGH RQ-PCR for MRD Quantification in CLL Patients after Rituximab-Containing Immunochemotherapy – a Comparative Analysis in 574 Samples from the Randomized GCLLSG CLL8 Trial

Sebastian Boettcher, MD, Stephan Stilgenbauer, MD, PhD, Raymonde Busch, Monika Brüggemann, MD, PhD, Thorsten Raff, MD, Kirsten Fischer, MD, Günter Fingerle-Rowson, MD, PhD, Anna-Maria Fink, MD, Christiane Pott, MD, Hartmut Döhner, MD, PhD, Michael Hallek, MD, PhD, Michael Kneba, MD, PhD, Matthias Ritgen, MD, on Behalf Of GCLLSG

Blood (2008) 112 (11): 3139.

https://doi.org/10.1182/blood.V112.11.3139.3139

Published: 2008

Journal Articles

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG).

Kirsten Fischer, MD, Stephan Stilgenbauer, MD, Carmen D. Schweighofer, MD, Jasmin Renschler, Raymonde Busch, Michael Kiehl, MD, Leopold Balleisen, MD, Michael Eckart, MD, Anna M. Fink, MD, Sebastian Boettcher, MD, Matthias Ritgen, MD, Michael Kneba, MD, Peter Staib, MD, Hartmut Doehner, MD, Barbara F. Eichhorst, MD, Michael Hallek, MD, Clemens-Martin Wendtner, MD, the German CLL Study Group (GCLLSG)

Blood (2007) 110 (11): 3106.

https://doi.org/10.1182/blood.V110.11.3106.3106

Published: 2007

Journal Articles

Early and Risk-Adapted Therapy with Fludarabine in High-Risk Binet Stage A CLL Patients Prolongs Progression Free Survival but Not Overall Survival: Results of the CLL1 Protocol of the German CLL Study Group (GCLLSG).

Manuela A. Bergmann, MD, Barbara F. Eichhorst, MD, Raymonde Busch, Hartmut Doehner, MD, Ursula Vehling-Kaiser, MD, Wolfgang Abenhardt, MD, Michael Hallek, MD, GCLLSG

Blood (2007) 110 (11): 2038.

https://doi.org/10.1182/blood.V110.11.2038.2038

Published: 2007

Journal Articles

Dose Escalation Study To Evaluate Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and Safety of Alemtuzumab for Consolidation Therapy in Patients with Chronic Lymphoycytic Leukemia: Phase I/II Trial of the German CLL Study Group (GCLLSG).

Kirsten Fischer, MD, Carmen D. Schweighofer, MD, Matthias Ritgen, MD, Sebastian Boettcher, MD, Elena Scharf, Barbara F. Eichhorst, MD, Raymonde Busch, Wolfgang Abenhardt, MD, Michael Kneba, MD, Michael Hallek, MD, Clemens-Martin Wendtner, MD, the German CLL Study Group (GCLLSG)

Blood (2007) 110 (11): 2053.

https://doi.org/10.1182/blood.V110.11.2053.2053

Published: 2007

Journal Articles

Prospective Evaluation of Prognostic Parameters in Early Stage Chronic Lymphocytic Leukemia (CLL): Results of the CLL1-Protocol of the German CLL Study Group (GCLLSG).

Manuela A. Bergmann, MD, Barbara F. Eichhorst, MD, Raymonde Busch, Dagmar Adorf, MD, Stephan Stilgenbauer, MD, Michael J. Eckart, MD, Clemens-Martin Wendtner, MD, Michael Hallek, MD, GCLLSG

Blood (2007) 110 (11): 625.

https://doi.org/10.1182/blood.V110.11.625.625

Published: 2007

Journal Articles

No Significant Clinical Benefit of First Line Therapy with Fludarabine (F) in Comparison to Chlorambucil (Clb) in Elderly Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Phase III Study of the German CLL Study Group (GCLLSG).

Barbara F. Eichhorst, MD, Raymonde Busch, Martina Stauch, MD, Manuela Bergmann, MD, Matthias Ritgen, MD, Nicole Kranzhöfer, MD, Carmen D. Schweighofer, MD, Kirsten Fischer, MD, Anna-Maria Fink, MD, Paula Cramer, Valentin Goede, MD, Clemens M. Wendtner, MD, Michael Hallek, MD, GCLLSG

Blood (2007) 110 (11): 629.

https://doi.org/10.1182/blood.V110.11.629.629

Published: 2007

Journal Articles

CHOP Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Hemolytic Anemia (AIHA) or Richter’s Transformation (RT): First Interim Analysis of a Phase II Trial of the German CLL Study Group (GCLLSG).

Barbara F. Eichhorst, MD, Raymonde Busch, Ulrich Duehrsen, MD, Holger Schulz, MD, Clemens M. Wendtner, MD, Maria E. Goebeler, MD, Michael Hallek, MD, and GCLLSG

Blood (2005) 106 (11): 2126.

https://doi.org/10.1182/blood.V106.11.2126.2126

Published: 2005

Journal Articles

17p Deletion Predicts for Inferior Overall Survival after Fludarabine - Based First Line Therapy in Chronic Lymphocytic Leukemia: First Analysis of Genetics in the CLL4 Trial of the GCLLSG.

Stephan Stilgenbauer, MD, Alexander Kröber, MD, Raymonde Busch, PhD, Barabara Eichhorst, MD, Dirk Kienle, MD, Dirk Winkler, MD, Georg Hopfinger, MD, Peter Lichter, MD, Bertold Emmerich, MD, Michael Hallek, MD, Hartmut Döhner, MD, The GCLLSG

Blood (2005) 106 (11): 715.

https://doi.org/10.1182/blood.V106.11.715.715

Published: 2005

Journal Articles

Comparison of the Efficacy and Toxicity of Fludarabine (F) in First Line Therapy of Younger Versus Elderly Patients (Pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Meta-Analysis of Two Phase III Trials of the German CLL Study Group (GCLLSG).

Barbara F. Eichhorst, MD, Raymonde Busch, Clemens M. Wendtner, MD, Michael Hallek, MD, GCLLSG

Blood (2005) 106 (11): 717.

https://doi.org/10.1182/blood.V106.11.717.717

Published: 2005

Journal Articles

Subcutaneous Campath-1H (Alemtuzumab) in Fludarabine-Refractory Cll: Interim Analysis of the CLL2h Study of the German Cll Study Group (GCLLSG).

Stephan Stilgenbauer, MD, Dirk Winkler, MD, Alexander Kröber, MD, Dirk Kienle, MD, Michael Hallek, MD, Manfred Hensel, MD, Eva Lengfelder, MD, Lorenz Trümper, MD, Peter Dreger, MD, Ulrich Jäger, MD, Hartmut Döhner, MD, the GCLLSG

Blood (2004) 104 (11): 478.

https://doi.org/10.1182/blood.V104.11.478.478

Published: 2004

NARROW

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis

Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL: A Multicenter Phase II Trial of the German CLL Study Group (GCLLSG).

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

Quantitative MRD Assessments Predict Progression Free Survival in CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab – a Prospective Analysis in 471 Patients from the Randomized GCLLSG CLL8 Trial

Standardized MRD Flow and ASO IGH RQ-PCR for MRD Quantification in CLL Patients after Rituximab-Containing Immunochemotherapy – a Comparative Analysis in 574 Samples from the Randomized GCLLSG CLL8 Trial

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG).

Early and Risk-Adapted Therapy with Fludarabine in High-Risk Binet Stage A CLL Patients Prolongs Progression Free Survival but Not Overall Survival: Results of the CLL1 Protocol of the German CLL Study Group (GCLLSG).

Dose Escalation Study To Evaluate Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and Safety of Alemtuzumab for Consolidation Therapy in Patients with Chronic Lymphoycytic Leukemia: Phase I/II Trial of the German CLL Study Group (GCLLSG).

Prospective Evaluation of Prognostic Parameters in Early Stage Chronic Lymphocytic Leukemia (CLL): Results of the CLL1-Protocol of the German CLL Study Group (GCLLSG).

No Significant Clinical Benefit of First Line Therapy with Fludarabine (F) in Comparison to Chlorambucil (Clb) in Elderly Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Phase III Study of the German CLL Study Group (GCLLSG).

CHOP Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Hemolytic Anemia (AIHA) or Richter’s Transformation (RT): First Interim Analysis of a Phase II Trial of the German CLL Study Group (GCLLSG).

17p Deletion Predicts for Inferior Overall Survival after Fludarabine - Based First Line Therapy in Chronic Lymphocytic Leukemia: First Analysis of Genetics in the CLL4 Trial of the GCLLSG.

Comparison of the Efficacy and Toxicity of Fludarabine (F) in First Line Therapy of Younger Versus Elderly Patients (Pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Meta-Analysis of Two Phase III Trials of the German CLL Study Group (GCLLSG).

Subcutaneous Campath-1H (Alemtuzumab) in Fludarabine-Refractory Cll: Interim Analysis of the CLL2h Study of the German Cll Study Group (GCLLSG).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only